BGB 16673
Alternative Names: BGB-1663; BGB-16673; Chimeric Degradation Activating Compound (CDAC) targeting BTK - BeiGeneLatest Information Update: 16 Oct 2024
At a glance
- Originator BeiGene
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Phase I Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
Most Recent Events
- 10 Oct 2024 BeiGene plans a phase I/II trial for B-cell-lymphoma (second-line or greater therapy) in December 2024 (NCT06634589)
- 26 Aug 2024 BGB 16673 receives Fast Track designation for Chronic lymphocytic leukaemia [PO] (Second-line therapy or greater) in USA
- 07 Aug 2024 BeiGene plans a phase III trial for Chronic lymphocytic leukemia in fourth quarter of 2024 or first quarter of 2025